Given that (1) TUBB3 expression and (2) dysfunction of SFKs both are associated with poor outcomes in a variety of solid cancers, a deeper understanding of the interplay between SFKs and β-tubulin in advanced prostate cancer could also improve clinical treatment of other solid cancers, including breast cancer and NSCLC. This evidence concerns the gene TUBB3 and prostate carcinoma.